Generic Name and Formulations:
Retapamulin 1%; oint.
Indications for ALTABAX:
Topical treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes in patients ≥9 months of age.
Adults and Children:
<9 months: not recommended. ≥9 months: apply thin layer to affected area (up to 100cm2 in total area in adults or 2% total body surface area in children) twice daily for 5 days. May cover with bandage or gauze dressing. Reevaluate if no improvement in symptoms within 3–4 days after starting treatment.
Not for intraoral, intranasal, ophthalmic, or intravaginal use. Discontinue if irritation or sensitization occurs. Prolonged use may result in superinfection. Pregnancy (Cat.B). Nursing mothers.
Application site irritation.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine